- Treating intellectual property as an investment, and subjecting it to treaty arbitration, can have undesirable impact
- The expanding universe of IP
- CCI to investigate Swiss drugmaker Roche over breast cancer biosimilar
- Indian competition commission issues a path breaking order on abuse of dominant position in pharmaceuticals
- TPP May Be Dead but Big Pharma’s Still Getting Away with Murder
Two years ago, the European Ombudsman ruled that the European Medicines Agency should open up access to Clinical Trial Data for anyone who applied from anywhere in the world.
Six months ago two American pharmaceutical companies AbbVie and InterMune took a legal action against EMA that has closed down access to all trial data for all drugs for all doctors and researchers anywhere in the world..
Some of you may not have heard of AbbVie. Until recently they were Abbott Laboratories, one of the biggest pharmaceutical companies in the world.
They make Humira, a monoclonal antibody used for Rheumatoid Arthritis, Crohn’s Disease, Psoriasis and other conditions. It is the best selling drug in the world today, and projected to be the best selling drug of all time.
This is one of the most important legal actions in Healthcare ever. At a recent meeting in Bruxelles AbbVie made it clear that a main reason to keep clinical trial data confidential was to hide adverse event data, and perhaps even as part of a Trade War..
Sign the petition here